FindTrial
Sign In

EFFECTS OF PROSTAGLANDIN COMPOUNDS ON CONJUNTIVAL MELANOGENESIS: AN IMPRESSION CITOLOGY AND TYROSINASE MARKERS STUDY - PGMECON

EFFECTS OF PROSTAGLANDIN COMPOUNDS ON CONJUNTIVAL MELANOGENESIS: AN IMPRESSION CITOLOGY AND TYROSINASE MARKERS STUDY - PGMECON

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-002941-35-IT
Enrollment
Unknown
Registered
2007-05-16
Start date
2006-07-31
Completion date
Unknown
Last updated
2012-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EVALUATION OF CONJUNTIVAL MELANOGENESIS IN HEALTHTY VOLOUNTEERS AND GLAUCOMATOUS PATIENTS IN THERAPY WITH PROSTAGLANDIN COMOUNDS MedDRA version: 6.1 Level: PT Classification code 10018304

Interventions

Trade Name: XALATAN*GTT OFT 1FL 0,005% 2,5 Pharmaceutical Form: Eye drops, solution INN or Proposed INN: Latanoprost CAS Number: 130209-82-4 Concentration unit: µg microgram(s) Concentration type: equ

Sponsors

AZIENDA OSPEDALIERA S. LUIGI GONZAGA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: USE OF PROSTAGLANDIN COMPOUNDS Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: SYSTEMIC INFLAMMATORY DISEASES

Design outcomes

Primary

MeasureTime frame
Main Objective: EVALUATION OF CONJUNTIVAL MELANOGENESIS UNDER PROSTAGLANDIN EFFECT;Secondary Objective: SAFETY;Primary end point(s): EVALUATION OF CONJUNTIVAL MELANOGENESIS UNDER PROSTAGLANDIN EFFECT—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026